Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Rocon who wrote (13245)	8/13/1998 6:50:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Rocon, I see no reason why they can't beat .09. They have restructured and eliminated many costs including the salesforce and much of the total employee count. The payroll is now cut to the bone. International sales will be solid. The gravy above .09 will be determined by what the domestic front does during the months of August and July. I expect to see a significant increase in domestic scripts over the next 2 months. I think we will see new scripts up to between 4,000 and 5,000 by the end of September. I was told by Vivus that they expect that new scripts would double soon after a strong domestic partner is signed up. VLAD PS A fund manager on CNBC just said that in today's market he is targeting small cap stocks that at current prices have "strategic aquisition value". I think Vivus currently fits the profile.